Led · Equity · Aug 2025

Green Steel Environmental is a U.S.-based company developing safer, chemical-free solutions for wastewater and biogas treatment. Led by Jon Jonis, the company is advancing alternatives that let utilities manage treatment systems without relying on toxic compounds. Its solutions aim to reduce the expense, handling risks, and environmental damage associated with traditional chemicals. On August 11, 2025, Green Steel Environmental raised $1.7M to support expansion and product development. The company intends to use the funds to expand operations and continue development efforts. The round signals early investor interest from regional angel groups and strategic partners as the company scales.

Led · Seed · Aug 2025

Swirltex develops a patented membrane membrane system designed to treat challenging wastewater streams that conventional systems cannot handle. Its system produces high-quality permeate with higher throughput, lower energy consumption, and operation across a broader range of climates. The company positions treated wastewater as a reusable resource. Led by founder Peter Christou, Swirltex is deploying its technology within operations. The company intends to use recent funding to expand operations and advance development efforts. Swirltex is headquartered in Calgary, Canada.

Participated · Series A · Jun 2025

Rebel Medicine is a clinical-stage biotechnology company headquartered in Salt Lake City that develops proprietary drug-delivery technologies to extend the duration of validated active pharmaceutical ingredients. Its lead product, Alevatrix™, is a novel long-acting formulation of bupivacaine encapsulated in the company's injectable matrix designed to release drug at the site of administration for up to 72 hours. In preclinical studies Alevatrix demonstrated prolonged, multi-day non-opioid analgesia with a favorable safety profile. The company has opened an Investigational New Drug (IND) application with the U.S. FDA for Alevatrix and plans a first-in-human, randomized, dose-escalation, active-controlled Phase 2 trial in bunionectomy patients. Rebel is advancing additional pipeline programs that use its delivery systems to provide extended-release of injectable drugs from days to months. The company closed a $6 million Series A to support clinical development and accelerate its opioid-sparing pain therapeutic programs.

Participated · Seed · Jan 2022

Inovues develops retrofittable insulating glass technology (branded Glazing Shield™) that enables building owners to add energy-saving and smart glass features without removing or replacing existing windows. The company began offering its insulating glass retrofits in 2020 after three years of R&D and has since installed its product on buildings throughout the U.S. Inovues is led by founder and CEO Anas Al Kassas and is based in Houston, TX. The product is patented and positioned for commercial rollout and wider adoption across existing building stock. The company intends to use new funding to grow its team, expand commercialization efforts, and scale adoption of its Glazing Shield™ technology.

Participated · Series A · Dec 2020

Aperiomics, founded in 2014 and based in Sterling, Virginia, develops a next‑generation genomic testing platform designed to identify every known pathogen from a single sample. The company quickly launched a COVID-19 test in March. Management says the platform will be made available to more doctors and integrated into the healthcare system as a new gold standard in diagnostic testing. Financially, Aperiomics closed its Series A at $3 million after adding $1.2 million to an initial $1.8 million announced in August 2019. The company has also launched a $1 million bridge note to fund operations until a Series B; the bridge is led by Tamiami Angel Fund IV, which has committed $300,000 and will include executive investments. Series A investors include VentureSouth, Pipeline Angels, Atlanta Technology Angels, The Launch Place and the Central Texas Angel Network. Aperiomics applies Deep Shotgun Metagenomic Sequencing and the Xplore-PATHOSM test to identify every bacterium, virus, fungus and parasite known to modern science. The Xplore-PATHOSM Test combines advanced DNA testing, big data and infectious disease expertise to identify the root cause of infectious diseases. By offering unbiased microbial insight, the company aims to help healthcare providers prescribe more precise treatments. Led by CEO Dr. Crystal Icenhour, Aperiomics recently expanded into a new 4,700 square foot facility in Sterling, Virginia and is constructing an on-site laboratory to be completed and certified in the coming months. The company plans to use new funding to increase the number of patients served and clinicians partnered with, and to make major investments in research and development.